Pulmonx Shares Slide Following Revised Guidance and Downgrades

Pulmonx shares are trading lower after the company revised its full-year 2025 revenue guidance down to $90-$92 million from previous expectations, and Piper Sandler downgraded its rating to 'Neutral' with a price target of $2.50.